CSL Wins ISPE’s 2025 Facility of the Year Award

CSL’s Broadmeadows Facility Recognized for Pharma 4.0 Integration and Sustainable Plasma Manufacturing

BROADMEADOWS, AUSTRALIA, Oct. 26, 2025 – CSL’s core plasma fractionation facility in Broadmeadows, Australia, has been awarded the prestigious 2025 Facility of the Year Award (FOYA) by the International Society for Pharmaceutical Engineering (ISPE), securing the coveted title of Overall Winner.

The purpose-built facility is engineered to optimize the production of plasma-derived therapies crucial for treating conditions ranging from immunodeficiencies and neurological disorders to severe burns. What sets Broadmeadows apart is its sophisticated integration of cutting-edge technologies and a pioneering hybrid manufacturing platform. This includes advanced automation, real-time production monitoring powered by sophisticated analytics, robotics for precision handling, and a digital twin infrastructure that enables flexible, multi-process manufacturing.

The shift toward paperless execution and a commitment to continuous improvement are also hallmarks of the Broadmeadows facility. The modular design is particularly noteworthy, providing scalability to meet growing demands and long-term adaptability to future technological advancements, a crucial factor as the biopharmaceutical industry navigates increasing complexity and regulatory scrutiny.

These technological leaps have translated to a nine-fold increase in plasma processing capacity, now exceeding 10 million liters annually. Beyond increased volume, internal data suggests significant enhancements in efficiency and yield, allowing CSL to broaden its reach and impact the lives of a greater number of patients worldwide. From a business perspective, this translates to improved economies of scale and a stronger competitive advantage in a rapidly evolving global market.

“This award reflects CSL’s dedication to innovation, operational excellence, and sustainability, positioning Broadmeadows as a global leader in next-generation biopharmaceutical manufacturing,” stated Andrew Hodder, VP Manufacturing and Site Head at Broadmeadows. “The Facility of the Year Award is a testament to the hard work and collaborative spirit of our entire team across various functions and continents.”

The facility’s sustainable infrastructure is integral to CSL’s commitment to responsible innovation. This includes reusable filters drastically reducing waste, energy-efficient systems minimizing environmental impact, and a fully automated warehouse utilizing robotic vehicles for streamlined and sustainable material handling. “By combining automation, digital innovation, and sustainable design, we’ve created a facility that exceeds industry standards for pharmaceutical manufacturing and establishes a benchmark for responsible innovation,” emphasized Jeffrey Ball, Chief Sustainability Officer and Senior Vice President for EHS, Strategy & Engineering.

The Broadmeadows facility previously earned ISPE FOYA recognition in May 2025 in the Pharma 4.0 category, acknowledging its pioneering use of digital technologies and automation to revolutionize pharmaceutical manufacturing processes. This latest award as Overall Winner underscores the facility’s holistic approach, demonstrating how technological innovation and sustainability can be integrated to achieve both operational efficiency and environmental responsibility.

About CSL

CSL (ASX: CSL; USOTC: CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita

For more information about CSL, visit CSL.com.